Every material Form 8-K CRYO CELL INTERNATIONAL INC has filed with the SEC since March 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cryo-Cell International's Board has set October 27, 2026 as the date for its 2026 Annual Meeting of Stockholders, with September 21, 2026 as the record date for stockholders entitled to vote. The filing also notes that the bylaw deadlines for stockholder proposals and director nominations were July 27, 2026. This is a routine governance notice with no reported financial effect.
Annual Meeting of Stockholders scheduled for October 27, 2026
Record date for voting eligibility is September 21, 2026
Deadline for stockholder proposals and director nominations was July 27, 2026
Amended bylaws were previously filed as Exhibit 3.1 to a Form 8-K dated December 11, 2018
Cryo-Cell International received written notice on May 6, 2026 that NYSE Regulation accepted its plan to regain compliance with NYSE American continued listing standards. The company's common stock will keep trading on NYSE American during a plan period ending September 9, 2027, but the company says it cannot assure it will regain compliance by then, and NYSE American may begin delisting proceedings if it does not.
NYSE Regulation accepted the compliance plan the company submitted on April 8, 2026, and granted a plan period through September 9, 2027.
The deficiencies cited are a stockholders' deficit as of November 30, 2025, and net losses in two of the three most recent fiscal years.
Common stock continues to be listed and traded on NYSE American, subject to the plan's initiatives and periodic review.
If the company fails to regain compliance by the deadline or make progress under the plan, NYSE American may initiate delisting proceedings.
Cryo-Cell International received a March 9, 2026 notice from NYSE American stating it does not meet Section 1003(a) of the NYSE American Company Guide, citing a stockholders' deficit as of November 30, 2025 and net losses in two of its three most recent fiscal years. The notice has no immediate effect on trading, and the company plans to submit a compliance plan by April 8, 2026, but there is no assurance NYSE American will accept the plan or that compliance will be regained.
NYSE American notice received March 9, 2026, under Section 1003(a) of the Company Guide
Cited a stockholders' deficit as of November 30, 2025, and net losses in two of the three fiscal years ended November 30, 2023, 2024 and 2025
Common stock continues to trade as CCEL; compliance plan due by April 8, 2026; if accepted, the company is typically granted up to 18 months from receipt of the notice
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CRYO CELL INTERNATIONAL INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →